U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C13H16N2.ClH
Molecular Weight 236.74
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TETRAHYDROZOLINE HYDROCHLORIDE

SMILES

Cl.C1CN=C(N1)C2CCCC3=C2C=CC=C3

InChI

InChIKey=BJORNXNYWNIWEY-UHFFFAOYSA-N
InChI=1S/C13H16N2.ClH/c1-2-6-11-10(4-1)5-3-7-12(11)13-14-8-9-15-13;/h1-2,4,6,12H,3,5,7-9H2,(H,14,15);1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C13H16N2
Molecular Weight 200.2795
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Tetrahydrozoline is an alpha adrenergic receptor agonist, which is used in form of nasal solution or spray (Tyzin) for decongestion of nasal and nasopharyngeal mucosa.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL2095203
Sources: www.ncbi.nlm.nih.gov/pubmed/18259967
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
TYZINE

Approved Use

Tyzine Nasal Solution is indicated for decongestion of nasal and nasopharyngeal mucosa.

Launch Date

1979
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.218 ng/mL
2 drop 4 times / day multiple, ocular
dose: 2 drop
route of administration: Ocular
experiment type: MULTIPLE
co-administered:
TETRAHYDROZOLINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3.46 ng × h/mL
2 drop 4 times / day multiple, ocular
dose: 2 drop
route of administration: Ocular
experiment type: MULTIPLE
co-administered:
TETRAHYDROZOLINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6 h
2 drop 4 times / day multiple, ocular
dose: 2 drop
route of administration: Ocular
experiment type: MULTIPLE
co-administered:
TETRAHYDROZOLINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
7500 ug single, oral
Overdose
Dose: 7500 ug
Route: oral
Route: single
Dose: 7500 ug
Sources:
healthy, 16 years
n = 1
Health Status: healthy
Age Group: 16 years
Sex: M
Population Size: 1
Sources:
Other AEs: Sinoatrial node dysfunction...
Other AEs:
Sinoatrial node dysfunction (1 patient)
Sources:
0.3 mg/kg single, oral
Overdose
Dose: 0.3 mg/kg
Route: oral
Route: single
Dose: 0.3 mg/kg
Sources:
healthy, 20 months-2 years
n = 2
Health Status: healthy
Age Group: 20 months-2 years
Sex: M+F
Population Size: 2
Sources:
Other AEs: Bradycardia, Hypertension...
Other AEs:
Bradycardia (2 patients)
Hypertension (1 patient)
Gasping (2 patients)
Sources:
250 ug 3 times / day multiple, oral
Overdose
Dose: 250 ug, 3 times / day
Route: oral
Route: multiple
Dose: 250 ug, 3 times / day
Sources:
unhealthy, 25 days
n = 1
Health Status: unhealthy
Age Group: 25 days
Sex: M
Population Size: 1
Sources:
Other AEs: Hypotonia...
Other AEs:
Hypotonia (1 patient)
Sources:
250 ug 3 times / day multiple, oral
Overdose
Dose: 250 ug, 3 times / day
Route: oral
Route: multiple
Dose: 250 ug, 3 times / day
Sources:
unhealthy, 25 days
n = 1
Health Status: unhealthy
Condition: mild fever
Age Group: 25 days
Sex: M
Population Size: 1
Sources:
Other AEs: Apnea...
Other AEs:
Apnea (1 patient)
Sources:
15000 ug single, oral
Overdose
Dose: 15000 ug
Route: oral
Route: single
Dose: 15000 ug
Sources:
healthy, 41 years
n = 1
Health Status: healthy
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Other AEs: Hypothermia, Bradycardia...
Other AEs:
Hypothermia (1 patient)
Bradycardia (1 patient)
Hypotension (1 patient)
Miosis (1 patient)
Lethargy (1 patient)
Mucous membrane disorder (NOS) (1 patient)
Bowel sounds decreased (1 patient)
Chest pain (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Sinoatrial node dysfunction 1 patient
7500 ug single, oral
Overdose
Dose: 7500 ug
Route: oral
Route: single
Dose: 7500 ug
Sources:
healthy, 16 years
n = 1
Health Status: healthy
Age Group: 16 years
Sex: M
Population Size: 1
Sources:
Hypertension 1 patient
0.3 mg/kg single, oral
Overdose
Dose: 0.3 mg/kg
Route: oral
Route: single
Dose: 0.3 mg/kg
Sources:
healthy, 20 months-2 years
n = 2
Health Status: healthy
Age Group: 20 months-2 years
Sex: M+F
Population Size: 2
Sources:
Bradycardia 2 patients
0.3 mg/kg single, oral
Overdose
Dose: 0.3 mg/kg
Route: oral
Route: single
Dose: 0.3 mg/kg
Sources:
healthy, 20 months-2 years
n = 2
Health Status: healthy
Age Group: 20 months-2 years
Sex: M+F
Population Size: 2
Sources:
Gasping 2 patients
0.3 mg/kg single, oral
Overdose
Dose: 0.3 mg/kg
Route: oral
Route: single
Dose: 0.3 mg/kg
Sources:
healthy, 20 months-2 years
n = 2
Health Status: healthy
Age Group: 20 months-2 years
Sex: M+F
Population Size: 2
Sources:
Hypotonia 1 patient
250 ug 3 times / day multiple, oral
Overdose
Dose: 250 ug, 3 times / day
Route: oral
Route: multiple
Dose: 250 ug, 3 times / day
Sources:
unhealthy, 25 days
n = 1
Health Status: unhealthy
Age Group: 25 days
Sex: M
Population Size: 1
Sources:
Apnea 1 patient
250 ug 3 times / day multiple, oral
Overdose
Dose: 250 ug, 3 times / day
Route: oral
Route: multiple
Dose: 250 ug, 3 times / day
Sources:
unhealthy, 25 days
n = 1
Health Status: unhealthy
Condition: mild fever
Age Group: 25 days
Sex: M
Population Size: 1
Sources:
Bowel sounds decreased 1 patient
15000 ug single, oral
Overdose
Dose: 15000 ug
Route: oral
Route: single
Dose: 15000 ug
Sources:
healthy, 41 years
n = 1
Health Status: healthy
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Bradycardia 1 patient
15000 ug single, oral
Overdose
Dose: 15000 ug
Route: oral
Route: single
Dose: 15000 ug
Sources:
healthy, 41 years
n = 1
Health Status: healthy
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Chest pain 1 patient
15000 ug single, oral
Overdose
Dose: 15000 ug
Route: oral
Route: single
Dose: 15000 ug
Sources:
healthy, 41 years
n = 1
Health Status: healthy
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Hypotension 1 patient
15000 ug single, oral
Overdose
Dose: 15000 ug
Route: oral
Route: single
Dose: 15000 ug
Sources:
healthy, 41 years
n = 1
Health Status: healthy
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Hypothermia 1 patient
15000 ug single, oral
Overdose
Dose: 15000 ug
Route: oral
Route: single
Dose: 15000 ug
Sources:
healthy, 41 years
n = 1
Health Status: healthy
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Lethargy 1 patient
15000 ug single, oral
Overdose
Dose: 15000 ug
Route: oral
Route: single
Dose: 15000 ug
Sources:
healthy, 41 years
n = 1
Health Status: healthy
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Miosis 1 patient
15000 ug single, oral
Overdose
Dose: 15000 ug
Route: oral
Route: single
Dose: 15000 ug
Sources:
healthy, 41 years
n = 1
Health Status: healthy
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Mucous membrane disorder (NOS) 1 patient
15000 ug single, oral
Overdose
Dose: 15000 ug
Route: oral
Route: single
Dose: 15000 ug
Sources:
healthy, 41 years
n = 1
Health Status: healthy
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Gingival tissue inflammatory response following treatment with chemical retraction agents in Beagle dogs.
2001
Viability of fibroblasts in cell culture after treatment with different chemical retraction agents.
2002 Jan
Electron microscopic analysis of the effects of chemical retraction agents on cultured rat keratinocytes.
2002 Jan
Gingival inflammatory response induced by chemical retraction agents in beagle dogs.
2002 Jan-Feb
Simultaneous determination of ofloxacin, tetrahydrozoline hydrochloride, and prednisolone acetate by high-performance liquid chromatography.
2002 Sep
Transdermal penetration of vasoconstrictors--present understanding and assessment of the human epidermal flux and retention of free bases and ion-pairs.
2003 Feb
[The tolerability of nasal drugs with special regard to preservatives and physico-chemical parameters].
2003 Nov
Sinoatrial node arrest following tetrahydrozoline ingestion.
2004 Oct
[Systemic involvement in premature infants after intranasal administration of tetryzoline drops].
2005 Oct
Simple HPLC determination of benzalkonium chloride in ophthalmic formulations containing antazoline and tetrahydrozoline.
2005 Sep-Oct
[Drug administration in newborns. Is clinical experience enough?].
2006 Apr
Antagonism by imidazoline-type drugs of muscarinic and other receptors in the guinea-pig ileum.
2006 Jul
Comparative evaluation of antimicrobial efficacy of sodium hypochlorite, MTAD, and Tetraclean against Enterococcus faecalis biofilm.
2007 Jul
Drug facilitated sexual assault using an over-the-counter ocular solution containing tetrahydrozoline (Visine).
2007 Jul
Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline.
2008 Feb
Patient use of Visine (tetrahydrozoline) masks Horner syndrome.
2008 Jan
Development of a multicommutated flow system with chemiluminometric detection for quantification of gentamicin in pharmaceuticals.
2010
Determination of tetrahydrozoline in urine and blood using gas chromatography-mass spectrometry (GC-MS).
2010
2-(1,2,3,4-Tetra-hydro-1-naphth-yl)imidazolium chloride monohydrate.
2010 Aug 18
A comparative kinetic and mechanistic study between tetrahydrozoline and naphazoline toward photogenerated reactive oxygen species.
2010 Jan-Feb
Naloxone use in a newborn with apnea due to tetrahydrozoline intoxication.
2010 Jun
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Tetrahydrozoline (Visine®) concentrations in serum and urine during therapeutic ocular dosing: a necessary first step in determining an overdose.
2011 Nov
Patents

Sample Use Guides

Adults and Children 6 Years and Over, Tyzine 0.1% Nasal Solution: It is recommended that 2 to 4 drops be instilled in each nostril as needed, never more often than every three hours. Adults and Children 6 Years and Over, Tyzine 0.1% Nasal Spray: It is recommended to squeeze quickly and firmly three or four times the spray in each nostril as needed, never more often than every three hours. Children 2 to 6 Years of Age, Tyzine 0.05 % Pediatric Nasal Drops: It is recommended that 2 to 3 drops be instilled in each nostril as needed, and never more often than every three hours.
Route of Administration: Nasal
In Vitro Use Guide
Rat and rabbit aortae were treated with tetrahydrozoline at concentrations from 10(-7) to 10(-5) M to determine the drug relative efficacy. Emax value was 0.51 for the rabbit aortae and 0 for the rat aortae.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:00:45 GMT 2023
Edited
by admin
on Fri Dec 15 15:00:45 GMT 2023
Record UNII
0YZT43HS7D
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TETRAHYDROZOLINE HYDROCHLORIDE
JAN   MI   ORANGE BOOK   USP   USP-RS   VANDF  
Common Name English
TETRAHYDROZOLINE HYDROCHLORIDE [JAN]
Common Name English
TETRYZOLINE HYDROCHLORIDE [MART.]
Common Name English
TYZINE
Brand Name English
TETRAHYDROZOLINE HCL
Common Name English
Tetryzoline hydrochloride [WHO-DD]
Common Name English
NSC-757339
Code English
TETRYZOLINE HYDROCHLORIDE
EP   MART.   WHO-DD  
Common Name English
YXIN
Brand Name English
TETRAHYDROZOLINE HYDROCHLORIDE [VANDF]
Common Name English
TETRAHYDROZOLINE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
TETRAHYDROZOLINE HYDROCHLORIDE [MI]
Common Name English
TETRAHYDROZOLINE HYDROCHLORIDE [USP-RS]
Common Name English
VISINE
Brand Name English
TETRAHYDROZOLINE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
TETRYZOLINE HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
RHINOPRONT
Brand Name English
Classification Tree Code System Code
CFR 21 CFR 349.18
Created by admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
NCI_THESAURUS C29709
Created by admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
Code System Code Type Description
DAILYMED
0YZT43HS7D
Created by admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
PRIMARY
EVMPD
SUB04765MIG
Created by admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
PRIMARY
SMS_ID
100000092231
Created by admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
PRIMARY
CHEBI
9492
Created by admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
PRIMARY
RXCUI
57983
Created by admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
PRIMARY RxNorm
ChEMBL
CHEMBL1266
Created by admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
PRIMARY
MERCK INDEX
m10634
Created by admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
PRIMARY Merck Index
ECHA (EC/EINECS)
208-329-3
Created by admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
PRIMARY
RS_ITEM_NUM
1652001
Created by admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
PRIMARY
FDA UNII
0YZT43HS7D
Created by admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
PRIMARY
DRUG BANK
DBSALT001254
Created by admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
PRIMARY
PUBCHEM
10648
Created by admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
PRIMARY
NCI_THESAURUS
C47749
Created by admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
PRIMARY
MESH
C005810
Created by admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
PRIMARY
EPA CompTox
DTXSID7045316
Created by admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
PRIMARY
NSC
757339
Created by admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
PRIMARY
CAS
522-48-5
Created by admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
USP
PARENT -> SALT/SOLVATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
ENANTIOMER -> RACEMATE
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
Ph.Eur.; USP
Related Record Type Details
ACTIVE MOIETY